MedWatch

Generic drugmaker Orifarm considers lawsuit against scandalized Indian CRO

Contract researcher Synchron Research Service helped Danish firm Orifarm with two of its generic medicines that are now facing the possibility of removal from the European market due to their links with the Indian organization.

Orifarm, which is based on the island of Funen, Denmark, is looking into its options after learning that two of its generic medicines marketed in its home country could be removed from market | Photo: Orifarm / PR

Orifarm, a parallel importer and seller of generic medicines, is reportedly looking into taking legal action against Indian contract research organization (CRO) Synchron Research Service following the news that the latter had conducted fraudulent drug trials

Two of Orifarm’s drugs on the Danish market were approved based on Synchron’s data, and are among the around 100 drugs that the European Medicines Agency (EMA) has recommended are removed from market by suspending market authorizations.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs